Impact of neoadjuvant chemotherapy combined with immunotherapy for the postoperative survival rate in patients with esophageal cancer
10.3760/cma.j.cn115396-20250827-00216
- VernacularTitle:食管癌新辅助化疗联合免疫治疗对患者术后生存率的影响
- Author:
Xiaodan HU
1
;
Jian CUI
Author Information
1. 北京市垂杨柳医院胸外科，北京 100022
- Keywords:
Esophageal neoplasms;
Chemotherapy, adjuvant;
Immunotherapy;
Survival rate
- From:
International Journal of Surgery
2025;52(11):761-766
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize and analyze the application value of neoadjuvant chemotherapy combined with immunotherapy in the surgical treatment of esophageal cancer.Methods:A retrospective case analysis method was used to summarize and analyze the clinical data of 73 esophageal cancer surgery patients admitted to Beijing Chuiyangliu Hospital from April 2018 to December 2023, including 60 males and 13 females, with an age of (63.9±9.29) years, ranged from 38 to 84 years. Among them, 58 patients with stage II or above received neoadjuvant chemotherapy and immunotherapy. The survival rates at 1, 3, and 5 years after surgery were statistically analyzed. Measurement data with normal distribution were represented as mean±standard deviation( ± s), and the comparison between groups was conducted using the t-test; the comparison of count data were represented as case and percentage (%) and was conducted by chi-square test. Kaplan-Meier method was applied to plot survival curves, and the Log-rank test was used for comparing survival rates. Results:In clinical staging, the 3 and 5 years survival rates of 73 patients in stage Ⅰ were 100%, the 3 years survival rate of stage Ⅱ was 88.2%, the 3 years survival rate of stage Ⅲ was 81.3%, and the 3 years survival rate of stage Ⅳ was 57.7%. There was no statistically significant difference in 3 years survival rates between patients in stage Ⅱ and stage Ⅰ( P>0.05), while there were statistically significant differences in 3 years survival rates between patients in stage Ⅲ, Ⅳ, and stage Ⅰ ( P<0.05). Among the 58 patients with pathological staging after neoadjuvant therapy, the 3 years survival rate of stage I was 80.8%, stage Ⅱ was 100%, stage Ⅲ was 81%, and stage Ⅳ was 27.8%. There was no statistically significant difference in 3 years survival rates among stage Ⅰ, Ⅱ, and Ⅲ patients ( P>0.05), but the 3 years survival rates of stage Ⅰ, Ⅱ, and Ⅲ patients were significantly higher than those of stage Ⅳ patients, and the differences were statistically significant ( P<0.05) when compared with stage Ⅳ. The 3 years and 5 years survival rates of patients with lymph node metastasis of stage N 0 were 91.2% and 68.4%, respectively. The 3 years survival rate of stage N 1 patients was 85.7%, stage N 2 patients was 72.2%, and stage N 3 patients was 0. There was no statistically significant difference in 3 years survival rate among patients with lymph node metastasis of stage N 0, N 1, and stage N 2( P>0.05). However, there was a significant statistical difference in 3 years survival rate between patients with lymph node metastasis of stage N 0, N 1, and stage N 3 ( P<0.01). Conclusion:Neoadjuvant chemotherapy combined with immunotherapy significantly improves the 3 years survival rate of patients with esophageal cancer, but the 3 years survival rate of stage Ⅳ patients and patients with lymph node metastasis of stage N 3 is still relatively low.
